Power Law company profile

Fate Therapeutics

Biotech & Life Sciences · San Diego, United States · Founded 2007 · IPO 2013 Unicorn

Stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics

Valuation

$19M

Market cap · May/2026

Revenue

$6.6M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

6 investors on Fate Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage

Venrock

ARCH Venture Partners

Polaris Partners

OVP Venture Partners

Series B+ 2 investors entered at this stage

Astellas Venture

University of Washington

Fate Therapeutics mafia

Startups founded by Fate Therapeutics alumni

Former Fate Therapeutics employees who went on to start their own companies. Sorted by Dealroom signal score.

Artiva BiotherapeuticsEst. 2019

Peter FlynnUnited States

Signal score83

Camp4 TherapeuticsEst. 2016

Leonard ZonUnited States

Signal score67

EvolutionaryScaleEst. 2023

Alex RivesUnited States

Signal score63

Stratus TherapeuticsEst. 2021

David ScaddenUnited States

Signal score62

ReceptosEst. 2009

WRWilliam RastetterUnited States

Signal score60

PellePharmEst. 2012

PBPhillip BeachyUnited States

Signal score58

StemgentEst. 2008

Sheng DingUnited States

Signal score58

Book a demo to explore the full alumni network →

Global footprint

Where Fate Therapeutics has talent and traffic

AI talent share

0.5% of workforce is AI talent
(1 of 222 staff)

Core AI00%

Other AI10.45%

Non-AI workforce22199.55%

Workforce by country

3 countries with
team presence

🇺🇸 United States98.8%

🇨🇳 China0.6%

🇪🇸 Spain0.6%

3 countries shown

Web traffic by country

7.8K monthly visits
across markets

🇺🇸 United States76.9%

🇮🇳 India11.5%

🇪🇸 Spain5.1%

🇲🇾 Malaysia5.1%

🇯🇵 Japan0%

Top 5 markets shown

Patent intelligence

$53M patent portfolio · 46 active families

Estimated portfolio value

$53M

280.7% of market cap · 38.1× smaller than top peer Ablynx ($2B)

46 active patent families

Where Fate Therapeutics innovates Molecular biologyEffector cellTherapeutic effectCombination therapyCell biology

Where Fate Therapeutics concentrates vs peers

Each axis is a top-10 topic across Fate Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Fate Therapeutics

An AI-synthesized read of the highest-engagement posts about Fate Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Fate Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles